The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
there is a disorder called remnant type 3 dyslipoprotinemia and that's a very specific highly atherogenic condition that manifests with high triglycerides high cholesterol but get this you know low apob so when i measure my lipids in april b i can recognize that but if you don't measure the apob and this applies to most of the people who are listening to this podcast if they go to see their doctors that condition can't be diagnosed
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
it's a commoner syndrome than familial hypercholesterolemia that gets day and night press day and night this one is easily treatable almost all the time fh needs to be treated much more challenging but type 3 cannot be diagnosed in most patients in the united states because apob is not measured